secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118261
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics Q3 2024 net loss narrows to $13.7M; advances Phase 3 trials for agitation
--------------------------------------------------------------------------------

- Net loss of $13.7M in Q3 2024 vs $50.5M loss in Q3 2023; operating cash use $16.3M.
- IGALMI net revenue $214k in Q3, down from $341k YoY; nine-month revenue $1.9M, up 89%.
- R&D expenses $5.1M vs $19.6M; SG&A $7.7M vs $24.3M, both lower due to restructuring.
- First patient randomized in SERENITY At-Home Phase 3 trial for bipolar/schizophrenia agitation; 9-12 month duration.
- Cash and equivalents $40.4M as of Sept 30, 2024; patent portfolio extended to 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/0001104659-24-118261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/tm2428378d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer